Thursday, November 14, 2024

Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.
Latest from Cancer Currents
11/14/2024
In a nearly 1,000-patient trial, treatment with nivolumab (Opdivo) and the chemotherapy regimen AVD was better at eliminating cancer and keeping it at bay than the current standard initial treatment for the disease, AVD and brentuximab (Adcetris). The nivolumab combination also had fewer side effects.
Read the Story

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Bookmark and Share

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

No comments:

Post a Comment

Volatility Sets Up a Black Friday Trade

Plus, new Power Factor stocks for your watchlist…   November 25, 2024 Volatility Sets Up a Black Friday Trade ...